Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Several studies have indicated that albuterol administered either intravenously or by
inhalation can significantly reduce plasma potassium concentration in patients suffering from
chronic renal failure.In conjunction with the decrease in potassium concentration a modest
rise in glucose concentration is usually noted. These metabolic effects are characterized by
rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting
for at least 1 hour.
The role played by ß2AR polymorphisms in determining the bronchial and vascular response to
ß2AR agonist drugs, have been confirmed by several studies.
The purpose of the present study is to examine possible causal relationships between
genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled
albuterol.